Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pharm Sci ; 113(8): 2542-2551, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38815860

RESUMEN

Rotigotine (RTG) is a dopamine agonist used in the treatment of Parkinson's disease. As it is susceptible to oxidation, stability studies must be carefully designed for the identification and characterization of all possible degradation products. Here, RTG degradation was evaluated according to the International Conference on Harmonization guidelines under various stress conditions, including acidic and basic hydrolysis, oxidative, metallic, photolytic, and thermal conditions. Additionally, more severe stress conditions were applied to induce RTG degradation. Significant degradation was only observed under oxidative and photolytic conditions. The samples were analyzed by high performance liquid chromatography coupled to photodiode array detectors, charged aerosol, and high-resolution mass spectrometry. Chromatographic analyses revealed the presence of eight substances related to RTG, four of which were already described and were qualified impurities (impurities B, C, K and E) and four new degradation products (DP-1 - DP-4), whose structures were characterized by high-resolution mass spectrometry through Q-Orbitrap and electrospray ionization. In the stress testing of the active pharmaceutical ingredient in solid form, significant RTG degradation was observed in the presence of the oxidative matrix. The results corroborate the literature that confirm the high susceptibility of RTG to oxidation and the importance of using different detectors to detect degradation products in forced degradation studies.


Asunto(s)
Estabilidad de Medicamentos , Espectrometría de Masa por Ionización de Electrospray , Tetrahidronaftalenos , Tiofenos , Cromatografía Líquida de Alta Presión/métodos , Tiofenos/química , Tiofenos/análisis , Espectrometría de Masa por Ionización de Electrospray/métodos , Tetrahidronaftalenos/química , Tetrahidronaftalenos/análisis , Oxidación-Reducción , Agonistas de Dopamina/análisis , Agonistas de Dopamina/química , Hidrólisis , Contaminación de Medicamentos/prevención & control , Fotólisis
2.
Drug Test Anal ; 10(11-12): 1657-1669, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30341930

RESUMEN

Zebrafish (Danio rerio) water tank (ZWT) approach was investigated as an alternative model for metabolism studies based on six different experiments with four model compounds. Sibutramine was applied for the multivariate optimization of ZWT conditions, also for the comparison of the metabolism among ZWT, humans and mice, beyond for the role of CYP2B6 in ZWT. After the optimization, 18 fish and 168 hours of experiments is the minimum requirement for a relevant panel of biotransformation products. A comparison among the species resulted in the observation of the same hydroxylated metabolites, with differences in metabolites concentration ratio. However, the ZWT allowed tuning of the conditions to obtain a specific metabolic profile, depending on the need. In addition, by utilizing CYP2B6 inhibition, a relevant ZWT pathway for the demethylation of drugs was determined. The stereospecificity of the ZWT metabolism was investigated using selegiline and no racemization or inversion transformations were observed. Moreover, the investigation of metabolism of cannabimimetics was performed using JWH-073 and the metabolites observed are the same described for humans, except for the hydroxylation at the indol group, which was explained by the absence of CYP2C9 orthologs in zebrafish. Finally, hexarelin was used as a model to evaluate studies by ZWT for drugs with low stability. As a result, hexarelin displays a very fast metabolization in ZWT conditions and all the metabolites described for human were observed in ZWT. Therefore, the appropriate conditions, merits, and relevant limitations to conduct ZWT experiments for the investigation of drug metabolism are described.


Asunto(s)
Preparaciones Farmacéuticas/metabolismo , Pez Cebra/metabolismo , Adulto , Animales , Antidepresivos/metabolismo , Antidepresivos/orina , Biotransformación , Ciclobutanos/metabolismo , Ciclobutanos/orina , Citocromo P-450 CYP2B6/metabolismo , Inhibidores del Citocromo P-450 CYP2B6/farmacología , Femenino , Humanos , Hidroxilación , Indoles/metabolismo , Indoles/orina , Masculino , Ratones , Modelos Animales , Naftalenos/metabolismo , Naftalenos/orina , Oligopéptidos/metabolismo , Oligopéptidos/orina , Preparaciones Farmacéuticas/orina , Selegilina/metabolismo , Selegilina/orina , Pez Cebra/orina , Proteínas de Pez Cebra/metabolismo
3.
Food Chem ; 210: 63-9, 2016 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-27211621

RESUMEN

Lutein is a carotenoid with antioxidant activity that is present in various dosage forms. The bioavailability of carotenoid from oral dosage formulations depends on their release, dissolution and its permeability through the gastrointestinal tract. Here, a dissolution test was developed for evaluating formulations and the bioavailability was assessed. The test utilized a USP-apparatus II with rotations of 50, 75 and 100rpm in water with P80 at 1, 2 and 5% (w/v). A non-everted rat intestinal sac model was used in conjunction to assess the intestinal permeability. The most discriminative conditions were 100rpm in water with 2% polysorbate 80, which showed profile differences between two formulations. The intestinal permeation studies showed a lag-time and apparent permeability coefficient that were characteristic of highly permeable drugs. We suggest that a dissolution test can be an essential quality control tool for formulations containing compounds as lutein, although not mandatory by the regulation agencies.


Asunto(s)
Mucosa Intestinal/metabolismo , Animales , Disponibilidad Biológica , Química Farmacéutica , Luteína/farmacología , Masculino , Permeabilidad/efectos de los fármacos , Ratas , Solubilidad , Comprimidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA